An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas

References

• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ): 2019 update. Eur Urol. 2019;76:639–657.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• David KA, Mallin K, Milowsky MI, et al. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer. 2009;115:1435–1447.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Yates DR, Comperat E, et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol. 2008;54:1226–1236.
   PubMed Web of Science ®Google Scholar
• Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10:2977.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–122.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Rink M, Margulis V, et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61:1069–1070.
   PubMed Web of Science ®Google Scholar
• Zigeuner RE, Hutterer G, Chromecki T, et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98:1181–1186.
   PubMed Web of Science ®Google Scholar
• Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008;101:1368–1374.
   PubMed Web of Science ®Google Scholar
• Li WM, Shen JT, Li CC, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010;57:963–969.
   PubMed Web of Science ®Google Scholar
• Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009;16:187–191.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Vander Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–2190.
   PubMed Web of Science ®Google Scholar
• Yuan H, Mao X, Bai Y, et al. The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. J Chemother. 2015;27:195–200.
   PubMed Web of Science ®Google Scholar
• Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011;60:955–960.
   PubMed Web of Science ®Google Scholar
• Knoedler JJ, Raman JD. Intracavitary therapies for upper tract urothelial carcinoma. Expert Rev Clin Pharmacol. 2018;11:487–493. .
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Maiti B, Bhattacharya S. First report of charge-transfer induced heat-set hydrogel. Structural insights and remarkable properties. Nanoscale. 2016;8:11224–11233.
   PubMed Web of Science ®Google Scholar
• Donin NM, Duarte S, Lenis AT, et al. Sustained-release formulation of Mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study. Urology. 2016;99:270–277.
   PubMed Web of Science ®Google Scholar
• Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, et al. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility. Urol Oncol. 2017;35:272–278.
   PubMed Web of Science ®Google Scholar
• UroGen Pharma Ltd. The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus). [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2020 Jul 21]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02793128?term=UGN-101+Olympus&draw=2&rank=1
   Google Scholar
• Kleinmann N, Matin S, Pierorazio P, et al. Nephron-sparing management of low-grade (LG) UTUC with UGN-101 (Mitomycin gel) for instillation: the Olympus trial experience. J Urol. 2019;201(Suppl. 4S):abs.LBA-16.
   Google Scholar
• Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020;21:776–785.
   PubMed Web of Science ®Google Scholar
• UroGen Pharma Ltd. Efficacy and safety of UGN-101 in recurrent patients (retreatment). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2020 Jul 21]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04006691?term=TC-UT-03%2FE&draw=2&rank=1.
   Google Scholar
• FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treatment-low-grade-upper-tract-urothelial-cancer (cited 2020 Jul 21).
   Google Scholar
• Serretta V. Optimizing intravesical chemotherapy in patient with non muscle invasive bladder carcinoma. Arch Ital Urol Androl. 2008;80:143–148.
   PubMedGoogle Scholar
• Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109:496–505.
   PubMed Web of Science ®Google Scholar
• Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of Gemcitabine vs Saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319:1880–1888.
   PubMed Web of Science ®Google Scholar
• Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2015;15:1379–1387.
   PubMed Web of Science ®Google Scholar
• Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197:1189–1199.
   PubMed Web of Science ®Google Scholar
• Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience. 2019;13:905.
   PubMed Web of Science ®Google Scholar
• Veeratterapillay R, Heer R, Johnson MI, et al. High -risk non-muscle invasive bladder cancer-therapy options during intravesical BCG shortage. Curr Urol Rep. 2016;17:68.
   PubMed Web of Science ®Google Scholar
• Packiam VT, Werntz RP, Steinberg GD. Current clinical trials in non-muscle-invasive bladder cancer: heightened need in an era of chronic BCG shortage. Curr Urol Rep. 2019;20:84.
   PubMed Web of Science ®Google Scholar